WO1996019239A1 - Composition solide a solubilite et absorbabilite ameliorees - Google Patents

Composition solide a solubilite et absorbabilite ameliorees Download PDF

Info

Publication number
WO1996019239A1
WO1996019239A1 PCT/JP1995/002611 JP9502611W WO9619239A1 WO 1996019239 A1 WO1996019239 A1 WO 1996019239A1 JP 9502611 W JP9502611 W JP 9502611W WO 9619239 A1 WO9619239 A1 WO 9619239A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid composition
powder
water
soluble drug
poorly water
Prior art date
Application number
PCT/JP1995/002611
Other languages
English (en)
Japanese (ja)
Inventor
Katsuhiko Yano
Atsushi Kajiyama
Shigeru Yamazaki
Naoki Itoh
Kazuhiro Sako
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to AU43141/96A priority Critical patent/AU4314196A/en
Publication of WO1996019239A1 publication Critical patent/WO1996019239A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

L'invention concerne une composition solide à solubilité et absorbabilité améliorées comprenant un médicament très difficilement soluble dans l'eau, dont la solubilité est inférieure ou égale à 10 νg/ml et qui se présente sous la forme suivante: substance amorphe, base polymère et tensioactif non ionique. Dispersée dans l'eau, cette composition forme des particules fines de taille inférieure ou égale à 1νm renfermant le médicament très difficilement soluble dans l'eau qui contient la substance amorphe. Dans ladite composition, le médicament très peu hydrosoluble est exsudé par les fines particules, ce qui améliore l'absorbtion du médicament à l'intérieur du tube digestif.
PCT/JP1995/002611 1994-12-21 1995-12-20 Composition solide a solubilite et absorbabilite ameliorees WO1996019239A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43141/96A AU4314196A (en) 1994-12-21 1995-12-20 Solid composition with improved solubility and absorbability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/318580 1994-12-21
JP31858094 1994-12-21

Publications (1)

Publication Number Publication Date
WO1996019239A1 true WO1996019239A1 (fr) 1996-06-27

Family

ID=18100727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/002611 WO1996019239A1 (fr) 1994-12-21 1995-12-20 Composition solide a solubilite et absorbabilite ameliorees

Country Status (2)

Country Link
AU (1) AU4314196A (fr)
WO (1) WO1996019239A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229846A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 放出制御型剤形
WO2002048141A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Composition medicinale dont la solubilite dans l'eau est amelioree
WO2002048142A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure absorbabilite
WO2003086405A1 (fr) * 2002-04-16 2003-10-23 Kowa Co., Ltd. Composition de dispersion solide
JP2004505911A (ja) * 2000-08-03 2004-02-26 ファイザー・プロダクツ・インク コレステリルエステル転移蛋白質阻害薬の医薬用組成物
WO2004030673A1 (fr) 2002-10-02 2004-04-15 Meiji Seika Kaisha, Ltd. Composition medicinale antibacterienne a absorptivite orale amelioree
WO2005034957A1 (fr) * 2003-10-08 2005-04-21 Meiji Seika Kaisha, Ltd. Composition antibacterienne non cristalline contenant du cefditoren pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
JP2006028131A (ja) * 2004-07-21 2006-02-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP2006056880A (ja) * 2004-07-21 2006-03-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP2007191419A (ja) * 2006-01-19 2007-08-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
WO2008114859A1 (fr) * 2007-03-22 2008-09-25 Astellas Pharma Inc. Composition pharmaceutique contenant un dérivé de pyrazole
JP2009506027A (ja) * 2005-08-26 2009-02-12 エスケー ケミカルズ カンパニー リミテッド 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
JP2009522278A (ja) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US7550158B2 (en) 1999-02-10 2009-06-23 Bend Research, Inc. Controlled release by extrusion of solid amorphous dispersions of drugs
WO2011105070A1 (fr) 2010-02-25 2011-09-01 パナソニック株式会社 Appareil et procédé de régulation par l'offre et la demande, et programme associé
US8026286B2 (en) 1999-12-23 2011-09-27 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
JP4780522B2 (ja) * 2003-11-14 2011-09-28 味の素株式会社 フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
US8257741B2 (en) 1997-08-11 2012-09-04 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
JP2014058584A (ja) * 2007-03-30 2014-04-03 Ajinomoto Co Inc 固体分散体製剤
US8697746B2 (en) 2010-07-14 2014-04-15 Senju Pharmaceutical Co., Ltd. Solid dispersion of alpha-ketoamide derivatives
US8828442B2 (en) 1999-02-10 2014-09-09 Bend Research, Inc. Pharmaceutical solid dispersions
JP2014177415A (ja) * 2013-03-13 2014-09-25 Daido Kasei Kogyo Kk ナノ粒子化製剤及びその製造方法
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US9050326B2 (en) 2008-04-02 2015-06-09 Astellas Pharma Inc. Amido derivatives-contained pharmaceutical composition
US9486410B2 (en) 2002-02-01 2016-11-08 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237913A (ja) * 1989-03-10 1990-09-20 Daito Koeki Kk 持続性製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237913A (ja) * 1989-03-10 1990-09-20 Daito Koeki Kk 持続性製剤

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431159B2 (en) 1997-08-11 2013-04-30 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US8257741B2 (en) 1997-08-11 2012-09-04 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US8263128B2 (en) 1997-08-11 2012-09-11 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US8337899B2 (en) 1997-08-11 2012-12-25 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US8367118B2 (en) 1997-08-11 2013-02-05 Bend Research, Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US7550158B2 (en) 1999-02-10 2009-06-23 Bend Research, Inc. Controlled release by extrusion of solid amorphous dispersions of drugs
JP2000229846A (ja) * 1999-02-10 2000-08-22 Pfizer Prod Inc 放出制御型剤形
US8828442B2 (en) 1999-02-10 2014-09-09 Bend Research, Inc. Pharmaceutical solid dispersions
US8796341B2 (en) 1999-12-23 2014-08-05 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
US8501231B2 (en) 1999-12-23 2013-08-06 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
US8026286B2 (en) 1999-12-23 2011-09-27 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
US8980321B2 (en) 1999-12-23 2015-03-17 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
US9457095B2 (en) 1999-12-23 2016-10-04 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
US8389011B2 (en) 2000-08-03 2013-03-05 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2007314573A (ja) * 2000-08-03 2007-12-06 Pfizer Prod Inc コレステリルエステル転移蛋白質阻害薬の医薬用組成物
JP2004505911A (ja) * 2000-08-03 2004-02-26 ファイザー・プロダクツ・インク コレステリルエステル転移蛋白質阻害薬の医薬用組成物
US8048452B2 (en) 2000-08-03 2011-11-01 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor
WO2002048142A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure absorbabilite
WO2002048141A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Composition medicinale dont la solubilite dans l'eau est amelioree
US9486410B2 (en) 2002-02-01 2016-11-08 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US10357455B2 (en) 2002-02-01 2019-07-23 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JPWO2003086405A1 (ja) * 2002-04-16 2005-08-18 興和株式会社 固体分散体組成物
WO2003086405A1 (fr) * 2002-04-16 2003-10-23 Kowa Co., Ltd. Composition de dispersion solide
WO2004030673A1 (fr) 2002-10-02 2004-04-15 Meiji Seika Kaisha, Ltd. Composition medicinale antibacterienne a absorptivite orale amelioree
USRE47033E1 (en) 2003-08-04 2018-09-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
JPWO2005034957A1 (ja) * 2003-10-08 2007-11-22 明治製菓株式会社 セフジトレンピボキシルを含有する非晶性抗菌組成物
WO2005034957A1 (fr) * 2003-10-08 2005-04-21 Meiji Seika Kaisha, Ltd. Composition antibacterienne non cristalline contenant du cefditoren pivoxil
US8518441B2 (en) 2003-11-14 2013-08-27 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
JP4780522B2 (ja) * 2003-11-14 2011-09-28 味の素株式会社 フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP4572293B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP2006056880A (ja) * 2004-07-21 2006-03-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP2006028131A (ja) * 2004-07-21 2006-02-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP4572296B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP2009506027A (ja) * 2005-08-26 2009-02-12 エスケー ケミカルズ カンパニー リミテッド 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2015096539A (ja) * 2005-12-28 2015-05-21 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
JP2009522278A (ja) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2014012701A (ja) * 2005-12-28 2014-01-23 Vertex Pharmaceuticals Inc Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2007191419A (ja) * 2006-01-19 2007-08-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP4572300B2 (ja) * 2006-01-19 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
WO2008114859A1 (fr) * 2007-03-22 2008-09-25 Astellas Pharma Inc. Composition pharmaceutique contenant un dérivé de pyrazole
JP5828616B2 (ja) * 2007-03-30 2015-12-09 味の素株式会社 固体分散体製剤
JP2014058584A (ja) * 2007-03-30 2014-04-03 Ajinomoto Co Inc 固体分散体製剤
US9050326B2 (en) 2008-04-02 2015-06-09 Astellas Pharma Inc. Amido derivatives-contained pharmaceutical composition
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
WO2011105070A1 (fr) 2010-02-25 2011-09-01 パナソニック株式会社 Appareil et procédé de régulation par l'offre et la demande, et programme associé
US8697746B2 (en) 2010-07-14 2014-04-15 Senju Pharmaceutical Co., Ltd. Solid dispersion of alpha-ketoamide derivatives
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2014177415A (ja) * 2013-03-13 2014-09-25 Daido Kasei Kogyo Kk ナノ粒子化製剤及びその製造方法
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
AU4314196A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
WO1996019239A1 (fr) Composition solide a solubilite et absorbabilite ameliorees
CA1146866A (fr) Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US6221402B1 (en) Rapidly releasing and taste-masking pharmaceutical dosage form
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
AU2002222567B2 (en) Composition improved in solubility or oral absorbability
AU2006222206B2 (en) Gastroresistant pharmaceutical formulations containing rifaximin
AU781881B2 (en) Cilostazol preparation
SK96299A3 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparing same
SK284145B6 (sk) Antifungálne prostriedky so zlepšenou biologickou dostupnosťou
JPH09183728A (ja) 固体薬剤調製物
JP2007504266A (ja) ジプラシドンの持続放出剤形
JP6339089B2 (ja) 非晶質トルバプタンを含有する経口投与懸濁剤
US20120294940A1 (en) Rapidly disintegrating tablet in oral cavity
US20100015225A1 (en) Solid dispersion of a neurokinin antagonist
JP2011148832A (ja) フェニルアラニン誘導体の徐放性経口投与製剤
JP2007063263A (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
CZ293062B6 (cs) Léčivo s regulovaným uvolněním aktivní sloučeniny
US20200061058A1 (en) Pharmaceutical formulation containing tadalafil
EP1652524A1 (fr) Sirop sec contenant de la loratadine
JP2016210799A (ja) 三種混合製剤
JPH08208476A (ja) ニフェジピン含有持続性製剤
KR100981750B1 (ko) 분무-건조 과립 및 그의 제조방법
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
EP1438961B2 (fr) Composition bioéquivalente sous la forme d'une dispersion solide comprenant de l'itraconazole et un polymer hydrophile
JP5241681B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KR KZ LK LR LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase